Overview

The global generic drug market for the inhalation and nasal spray therapeutic area continues its robust growth trajectory. By the end of 2025, it is projected that the global generic market for this therapeutic area will be valued at approximately $35.25 billion.

The sales of generic inhalers and nasal sprays is expected to increase even further following the continuous rise in the number of patients suffering from restrictive and even life-threatening respiratory diseases, such as Chronic Obstructive Pulmonary Disease (COPD), asthma, and allergic rhinitis. Global factors such as an aging population, rising air pollution, and increased diagnosis rates are the main drivers exacerbating the prevalence of these chronic respiratory conditions.
The incredibly high healthcare costs, especially in developed economies like the United States and Europe, is therefore driving this growing patient pool and healthcare payers towards generic drugs. The approval of key generic versions of branded combination inhalers is poised to accelerate cost savings and patient access significantly.

It is deduced that the global market for inhalation and nasal spray generic drugs is currently valued at approximately US$35.25 billion in 2025. This market is expected to display a Compound Annual Growth Rate (CAGR) of around 8.26% from 2025 to 2030, projecting the market to reach approximately $48.42 billion by 2030.